1. Home
  2. KOPN vs VTGN Comparison

KOPN vs VTGN Comparison

Compare KOPN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$5.00

Market Cap

396.8M

Sector

Technology

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.27

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOPN
VTGN
Founded
1984
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
396.8M
10.8M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
KOPN
VTGN
Price
$5.00
$0.27
Analyst Decision
Strong Buy
Hold
Analyst Count
4
3
Target Price
★ $4.69
$0.90
AVG Volume (30 Days)
2.9M
★ 18.2M
Earning Date
05-12-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 103.03
N/A
EPS
★ N/A
N/A
Revenue
★ $1,530,311.00
N/A
Revenue This Year
$50.07
$124.49
Revenue Next Year
$33.33
$353.99
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 46.53
N/A
52 Week Low
$1.81
$0.20
52 Week High
$6.61
$5.14

Technical Indicators

Market Signals
Indicator
KOPN
VTGN
Relative Strength Index (RSI) 59.92 51.92
Support Level $4.14 $0.22
Resistance Level $5.53 $0.32
Average True Range (ATR) 0.24 0.03
MACD 0.05 0.01
Stochastic Oscillator 89.16 13.72

Price Performance

Historical Comparison
KOPN
VTGN

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: